Whole-Body Diffusion-Weighted Magnetic Resonance Imaging (MRI) as a Response Biomarker for Metastatic Prostate Cancer

NCT05078151 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer Metastatic

Interventions

DIAGNOSTIC_TEST: Whole-Body Diffusion Weighted MRI

Sponsor

Vall d'Hebron Institute of Oncology

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]